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Background: High blood and tissue concentrations of glucose and advanced glycation end-products are believed
to play an important role in the development of vascular complications in patients with diabetes mellitus (DM) and
chronic kidney disease. MicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in a sequence
specific manner. MiRNA are involved in various biological processes and become novel biomarkers, modulators and
therapeutic targets for diseases such as cancer, atherosclerosis, and DM. Calcitriol (the active form of vitamin D) may
inhibit endothelial proliferation, blunt angiogenesis, and be a cardioprotective agent. Calcitriol deficiency is a risk
factor for DM and hypertension. The aim of this project was to study the miRNA microarray expression changes in
human umbilical vein endothelial cells (HUVEC) treated in a diabetic-like environment with the addition of calcitriol.
Methods: HUVEC were treated for 24 h with 200 μg/ml human serum albumin (HSA) and 100 mg/dl glucose
(control group) or 200 μg/ml AGE-HSA, and 250 mg/dl glucose (diabetic-like environment), and physiological
concentrations (10-10 mol/l) of calcitriol. miRNA microarray analysis and real time PCR to validate the miRNA
expression profile and mRNA target gene expression were carried out.
Results: Compared to control, 31 mature human miRNA were differentially expressed in the presence of a
diabetic-like environment. Addition of physiological concentrations of calcitriol revealed 39 differentially expressed
mature human miRNA. MiR-181c, miR-15a, miR-20b, miR-411, miR-659, miR-126 and miR-510 were selected for
further analysis because they are known to be modified in DM and in other biological disorders. The predicted
targets of these miRNA (such as KLF6, KLF9, KLF10, TXNIP and IL8) correspond to molecular and biological processes
such as immune and defense responses, signal transduction and regulation of RNA.
Conclusion: This study identified novel miRNA in the field of diabetic vasculopathy and might provide new
information about the effect of vitamin D on gene regulation induced by a diabetic-like environment. New gene
targets that are part of the molecular mechanism and the therapeutic treatment in diabetic vasculopathy are
highlighted.
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MicroRNAs (miRNA) are non-coding RNA species of
approximately 22 nucleotides that regulate gene expres-
sion in a sequence-specific manner. miRNA join to par-
tial complementary sequences in the 3'UTRs of target
mRNA of protein coding genes to specify translational
repression and/or mRNA cleavage [1,2]. miRNA are in-
volved in various biological processes and have become
novel biomarkers, modulators and therapeutic targets
for diseases such as cancer, heart disease, and diabetes
[1,2]. Several studies investigated the effect of miRNA
on the development of diabetes and its complications,
including endothelial and vascular smooth muscle cell
dysfunction, diabetic cardiomyopathy and diabetic ne-
phropathy, and demonstrated involvement of specific
types of miRNA, which regulate a broad range of in-
flammatory genes [3-5].
Diabetes mellitus (DM) is associated with endothelial
dysfunction including changes in barrier function and
homeostasis, reduced vasodilator response, inflammatory
activation, increased plasma levels of endothelial prod-
ucts, and angiogenesis, all of which are associated with a
greater incidence and severity of cardiovascular diseases
[6-10]. Hyperglycemia is thought to affect endothelial
function, increasing stiffness of the peripheral arteries
and arterioles partly due to reduced nitric oxide produc-
tion [8,10]. Elevated concentrations of environmental
glucose initiate events that stimulate extracellular and
intracellular formation of advanced glycation end prod-
ucts (AGEs) [10-12]. The increased formation of AGEs
plays a relevant role in the development of vascular and
renal-related complications seen in DM, chronic kidney
disease (CKD), and aging [11,12]. Previous studies per-
formed in our laboratory have demonstrated that AGEs
stimulate the endothelial expression of AGE receptor
(RAGE) and interleukin 6 (IL6), and depress the eNOS
mRNA expression and eNOS enzymatic activity [13,14],
while calcitriol blunted the deleterious effect of AGEs in
this in vitro model [14].
Our previous studies in endothelial and vascular smooth
muscle cells using a high throughput microarray approach
[15-17], showed that diabetic-like conditions (250 mg/dl
glucose and AGEs at a concentration similar to that found
in the blood of diabetic patients) induced significantly ele-
vated expressions of cellular and metabolic processes, in-
cluding endothelial inflammatory-related genes through
the NFκB pathway and stimulated the production of thior-
edoxin interacting protein (TXNIP). Calcitriol (1,25 dihy-
droxycholecalciferol), the active form of vitamin D that
controls calcium homeostasis, hormonal secretions, and
cell proliferation and differentiation, was found to have a
protective effect on the development of renal or cardiovas-
cular disorders in stimulated endothelial cells in vitro and
in vivo [18,19]. Vitamin D deficiency is a risk factor forDM and hypertension [20]. Our previous studies showed
that adding calcitriol to endothelial and vascular smooth
muscle cells significantly down-regulated the inflamma-
tory response of gene and protein expression involved in
the NFκB signal transduction pathway [16,17]. In this
study we evaluated the expression of miRNA and their
predicted gene targets in human umbilical vein cord endo-
thelial cells (HUVEC) exposed to a diabetic like environ-
ment and the effect of calcitriol on their expression.
Materials and methods
Cell culture and incubation
HUVEC were isolated from umbilical cords obtained from
the maternity unit at Meir Medical Center, Kfar Saba,
Israel [13]. The Ethical Review Committee approved the
study and the parturient provided written informed con-
sent. HUVEC were identified by their typical cobblestone
morphology and by immunostaining for von Willebrand
factor. HUVEC were grown in M-199 medium supple-
mented with 20% FCS, 100 U/ml penicillin, 100 μ/ml
streptomycin (Biological Industries, Bet Haemek, Israel),
5 U/ml heparin, and 25 μ/ml endothelial mitogen
(Biomedical Technologies Inc., Stoughton, MA, USA).
Confluent cultures of HUVEC were used for experiments
at passages 3–4. The cells were stimulated in media con-
taining 200 μg/μl HSA and 100 mg/dl glucose (control
group) or 200 μg/μl AGE-HSA and 250 mg/dl glucose
(diabetic-like environment) for 24 h. Calcitriol 10-10 mol/l
(PH&T SpA, Milan, Italy), corresponding to physiological
blood concentrations, [16,17] was added to cells 1 h after
having started the stimulation with AGE-HSA and glucose
for an additional 23 h.
miRNA microarray analysis
miRNA were extracted using the mirVANA™ RT-PCR
miRNA isolation and detection kit (Ambion, Austin, Texas,
USA) according to manufacturer’s instructions. RNA quan-
tity and quality were determined using Nanodrop (Thermo
Fisher Scientific, Inc, Wilmington, DE, USA). Affymetrix
GeneChip® miRNA 2.0 arrays were used for genome-wide
miRNA expression analysis (15,644 probe sets for 131 or-
ganisms, including 1,105 human miRNA, 1,105 human
pre-miRNA and 2,302 human small nucleolar RNAs) ac-
cording to the instruction manual, as described in URL 1
(Affymetrix, Santa Clara, CA, USA). Three biological re-
peats were used for each treatment.
Bioinformatics analysis
Microarray analysis was performed on CEL files using
Partek® Genomics Suite™ (Partek GS, Partek Inc., MO,
USA; Quantile normalization was performed by the ro-
bust multi-average method (RMA). Batch effect removal
was applied for the different samples to remove individ-
ual variations, followed by one-way analysis of variance
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pressed (p < 0.05; fold-change cutoff 1.5) were obtained.
Each relevant miRNA was analyzed using TargetScan,
which uses a computational algorithm to predict biological
gene targets of miRNA. David and WebGestalt databases
(http://david.abcc.ncifcrf.gov and http://bioinfo.vanderbilt.
edu/webgestalt, respectively) were used for functional an-
notations of the target gene lists. The String database
(http://string-db.org) was used to predict the miR-target-
interactions including direct (physical) and indirect (func-
tional) associations. Enrichment of GO biological pro-
cesses with FDR correction was used.
miRNA – real time PCR
miRNA real time PCR was performed on 2 additional
biological repeats (total of 5 repeats) using TaqMan spe-
cific Small RNA primer and probe sets for miR-181c,
miR-411, miR-659, miR-510, miR-126, miR-15a and miR-
20b (Applied Biosystems, Inc., Foster City, CA, USA).
miRNA expression is represented relative to the expres-
sion of the internal control U6-snRNA. Data were ana-
lyzed using the 2-ΔΔCt method.
RNA extraction and real-time PCR
Total RNA was extracted from HUVEC using mir-
VANA™ RT-PCR isolation and detection kit (Ambion,
Austin, Texas, USA) and RNeasy Mini Kit, including
DNase digestion with RNase-free DNase set (Qiagen,
Valencia, CA, USA) according to manufacturer's in-
structions. RNA integrity was assessed using NanoDrop
(Thermo Fisher Scientific, Inc, Wilmington, DE, USA).
RNA (1 μg) was then reverse transcribed into single-
strand DNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Inc, Foster City,
CA, USA), according to manufacturer's instructions.
TaqMan real-time PCR amplification was used with
gene specific primer for Kruppel-like Factor 6 (KLF6),
KLF9, KLF10 using glucuronidase, beta (GUSB) as con-
trol genes. Data were analyzed using the 2-ΔΔCt method.
Statistical analysis
All data are expressed as mean ± standard deviation (SD).
Friedman and repeated measures with Bonferroni multiple
comparisons were used to evaluate the effect of the differ-
ent treatments on the expression of selected miRNA. Stu-
dent t-test and Mann–Whitney non-parametric test were
used to evaluate the different treatments on the expres-
sion of selected target mRNA genes. P-values of 0.05 or
less were considered significant.
Results
Differentially expressed miRNA
MiRNA expression in cultured HUVEC exposed to a
diabetic-like environment revealed 31 mature humanmiRNA that were significantly changed (p < 0.05, fold
change cut-off 1.5), of which 18 were up-regulated and
13 were down-regulated (Figure 1A).
The addition of calcitriol (10-10 mol/l) to cultured
HUVEC exposed to a diabetic-like environment revealed
39 mature human miRNA that were significantly chan-
ged (p < 0.05 and fold-change cut-off 1.5), of which 19
miRNA were up-regulated and 20 were down-regulated
(Figure 1B). Table 1 presents a partial list of selected
miRNA (from the differential mature human miRNA)
that were chosen according to their p-value, their fold
changes or their physiological expression. From the
miRNA list presented in Table 1 and from the corre-
sponding Venn diagram (Figure 1C), we validated several
miRNA (marked in bold in Table 1) that are known to
be modified in a diabetic environment (miR-510, miR-
15a, miR-20b, miR-126, and miR-181C). miR-659 and
miR-411 were validated because in the microarray ana-
lysis they were significantly changed after the addition of
calcitriol. Each miRNA was normalized to that of the
U6-snRNA, which was used as a reference. A total of 5
biological repeats (5 different umbilical cords) were used
for the validation to ensure that the variations observed
were biological. The miRNA expression patterns (Figure 2,
A-G) were consistent between the microarray (insets) and
real-time PCR validations.
Gene target and pathway analysis of miR-181C, miR-15a
and miR-20b
MiRNA are known to regulate many target genes and
consequently can modulate different signaling pathways.
We focused on three differentially expressed miRNA:
miR-181C, miR-15a and miR-20b, which were found to
be down-regulated in a diabetic-like environment and
up-regulated after the addition of calcitriol. They were
chosen for further investigation because their gene tar-
gets play a key role in endothelial cell function, which is
relevant to our research (Table 2). We found that genes
targets from the Kruppel-like family, which are tran-
scription factors that play key regulatory roles in cellular
growth, differentiation, proliferation, apoptosis and angio-
genesis [20,21], take part as putative targets for miR-181C
and miR-20b. TXNIP, a pro-apoptotic protein, which is
known to regulate endothelial cell metabolism, growth,
and inflammation [22,23] and IL8, an inflammatory-
related protein [24] are putative targets of miR-20b and
miR-15a. Based on these target genes, using the String
database, we predicted the miRNA-target protein interac-
tions including direct (physical) and indirect (functional)
associations. Based on these results, we found that the
predicted gene targets correspond to biological processes
such as immune and defense responses, signal transduc-
tion and regulation of RNA and primary metabolic pro-
cesses (Figure 3). We decided to further analyze KLF6,
Figure 1 (See legend on next page.)
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Figure 1 Hierarchical clustering of miRNA expression in HUVEC. Seven focal miRNA are indicated with arrows at the bottom of the clusters
(A, B) and on the VENN diagram (C). Clusters represent treatment with (A) AGE-HSA and glucose 250 mg/dl (AGE-GLU) compared to control
(HSA and 100 mg/dl glucose concentration); (B) AGE-HSA, glucose 250 mg/dl and 10-10 mol/l calcitriol (AGE-GLU + vit. D) compared to AGE-HSA
and glucose 250 mg/dl (AGE-GLU); (C) Comparison between differentially expressed miRNA lists.
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time PCR analysis, we found that the expression level of
KLF6 was significantly up-regulated in a diabetic-like
environment (Figure 4). KLF9 and KLF10 were also up-
regulated, but not significantly. The addition of calcitriol
significantly down-regulated KLF6, KLF9 and KLF10
mRNA expression (Figure 4). TXNIP and IL8 expres-
sion patterns, as previously described, were significantly
up-regulated in a diabetic-like environment, whereas
the addition of calcitriol significantly down-regulated
IL8 [14,15].Table 1 Summary of miRNA in HUVEC exposed to a
diabetic environment with and without calcitrol
miRNA ID
Diabetic environmenta Diabetic environment
and calcitrol
Fold change p-value Fold change p-value
hsa-mir-600 1.53 0.014 -1.35 0.036
hsa-mir-10b 1.49 0.01 -1.31 0.032
hsa-mir-640 1.31 0.006 -1.35 0.004
hsa-miR-510 1.35 0.018 -1.49 0.03
hsa-miR-659 1.37 0.13 1.99 0.0005
hsa-mir-320e 1.88 0.002 -1.12 0.19
miR-425-star 1.8 0.01 -1.48 0.034
hsa-miR-181c -1.15 0.14 3.26 0.01
hsa-miR-411 -1.57 0.015 2.33 0.002Discussion
Endothelial cell, diabetic environment and vitamin D
The regulation of miRNA that are released in the endo-
thelium in response to a diabetic-like environment and
vitamin D might provide important insights to the events
that play a major role in the development of vascular
complications. Our previous studies showed that diabetic-
like conditions characterized by mildly elevated glucose
concentrations (250 mg/dl) and AGEs in an HUVEC cul-
ture model, were found to stimulate endothelial TXNIP
system activity, as well as expression of the inflammatory
related proteins IL6, IL8, RAGE, and NFκB [15]. Adding
physiological concentrations of calcitriol (10-10 mol/l) to
this in vitro model had a beneficial effect on the endothe-
lial expression of pro-inflammatory parameters, probably
through the NFκB signal transduction pathway [16].
Vitamin D was found to play an important role in renal,
endothelial, and cardiovascular protection and to have an-
titumor activity [18-20]. In this study, we used a miRNA
microarray to obtain expression profiles of miRNA in cul-
tured HUVEC that were exposed to a diabetic-like envir-
onment in order to mimic a clinical model of DM in vitro.
We demonstrated that stimulation of vitamin D in this
type of environment has a beneficial effect on the endo-
thelial expression of miRNA profile and their target genes.hsa-miR-133b -1.73 0.002 1.19 0.056
hsa-miR-613 -1.91 0.005 1.38 0.036
hsa-miR-335 -1.71 0.037 1.97 0.019
hsa-miR-642 -1.48 0.006 1.23 0.036
hsa-miR-670 -1.41 0.026 1.53 0.014
hsa-miR-20b -2.62 0.072 2.86 0.09
hsa-miR-15a -4.54 0.07 3.69 0.11
hsa-miR-126 -1.76 0.07 1.55 0.14
a200 μg/ml AGE-HSA and 250 mg/dl glucose vs. control (200 μg/μl HSA and
100 mg/dl glucose).Differentially expressed miRNA
We identified a list of miRNA that were differentially
expressed following the various manipulations. As men-
tioned previously, we focused on selected miRNAs that
are known to be modified in a diabetic-like environment
or that were highly changed after the addition of calci-
triol. MiR-510 and miR-659 were over-expressed under
diabetic-like conditions and decreased after calcitriol
was added. MiR-126, miR-411, miR-20b, miR-15a andmiR-181c were down-regulated under diabetic condi-
tions and over-expressed after calcitriol was added.
MiR-510 was first identified in association with irrit-
able bowel syndrome; its co-expression was involved in
the regulation of 5-HT3 receptors in colonic enterocytes
[23]. Recently, Hezova et al. [24] demonstrated that
miR-510 expression was elevated in regulatory T cells of
diabetic patients. To the best of our knowledge, our
findings are the first demonstration of miR-510 involve-
ment in HUVEC exposed to a diabetic-like environment
with significant changes induced by calcitriol. Manipula-
tion of miR-510 may represent a beneficial effect of cal-
citriol if we consider the possible deleterious effect of
increased miR-510 in DM. MiR-659 is not described in
the database as being connected to a diabetic-like envir-
onment and appears to be novel in genomic control in
the presence of diabetic-like conditions affected by vita-
min D. Further investigation of the effect of the miRNA
on their predicted target genes is warranted.
MiR-126 is highly enriched in endothelial cells and is
involved in vascular integrity, angiogenesis and wound
Figure 2 Validation of miRNA expression results by real time PCR. HUVEC were incubated for 24 h with HSA (200 μg/ml), AGE-HSA (200 μg/ml)
and glucose (250 mg/dl). In addition, 10-10 mol/l calcitriol was given to the cells 1 h after stimulation for an additional 23 h. The miRNA
set that included (A) miR-659, (B) miR-510, (C) miR-181C, (D) miR-411, (E) miR-126, (F) miR-15a, and (G) miR-20b was validated using real
time PCR. Insets show miRNA microarray expression results. Data are expressed as mean ± SD of 4–5 independent experiments. *P < 0.05 compared to
control group-HSA. **P < 0.05 compared with AGE-glucose.
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sistently associated with diabetes [27,28]. Zampetaki et al.
[27] found that high glucose concentrations (25 mmol/l
equivalent to 500 mg/dl) significantly reduced miR-126
expression in endothelial apoptotic bodies and improved
vascular growth factor (VEGF) signaling, leading to endo-
thelial dysfunction [27,29]. In patients with DM, low
plasma levels of miR-126 could be clinically relevant and
contribute to VEGF resistance and endothelial dysfunction
[30]. In this study, we also found in HUVEC a decreased
expression of miR-126 exposed to a diabetic like environ-










TXNIP TXNIP TXNIPelevated miR-126 expression, which can probably improve
VEGF signaling and repair endothelial dysfunction.
Differential expression of miR-411 was reported in a
miRNA profiling study of the hippocampus and the mar-
ginal division in a rat brain [30]. In addition, miR-411
was reported to be down-regulated in an autosomal
dominant muscle disorder (facioscapulohumeral muscu-
lar dystrophy) suggesting that reduction of miR-411
might have a positive effect on muscle regeneration and
promote myoblast maturation [31]. To our knowledge,
no study has investigated the effect of diabetes and vita-
min D on the function of miR-411 in endothelial cells.
The relevance of its role in diabetes remains unknown
and should be clarified in the future. The significant ef-
fect of vitamin D remains speculative at this stage.
Selected miRNAs and their target genes
MiR-15a, miR-20b and miR-181C were found to be down-
regulated in a diabetic-like environment and up-regulated
after the addition of calcitriol; they were chosen for fur-
ther investigation at the level of their gene targets, which
have been shown to be involved in the modulation of
endothelial function. MiR-15a, a cell growth suppressor,
was evaluated in human cancer cells and found to have a
pro-apoptotic role by activating caspase 3/7, which re-
duces cell viability [32]. In addition, miR-15a has been
correlated with different pathophysiological events in the
Figure 3 Predicted miRNA-target protein biological interactions, including direct and indirect associations. The predicted gene targets
were found to correspond to biological processes such as immune and defense responses, signal transduction and regulation of RNA and
primary metabolic processes. The genes that were further analyzed and discussed, KLF6, KLF9, KLF10, TXNIP and IL8 are marked with a ring.
These gene targets were chosen because they take part in cellular growth, differentiation, proliferation, apoptosis and angiogenesis, as well as in
regulating endothelial cell metabolism, growth, and inflammation.
Figure 4 Effect of calcitriol on target genes KLF6, KLF9 and
KLF10 mRNA expression in HUVEC stimulated with a
diabetic-like environment. HUVEC were incubated for 24 h with
HSA (200 μg/ml), AGE-HSA (200 μg/ml) and glucose (250 mg/dl). In
addition, 10-10 mol/l calcitriol was given to the cells 1 h after stimulation
for an additional 23 h. KLF6, KLF9 and KLF10 mRNA expression were
analyzed by real-time PCR and normalized to the GUSB. Data are
expressed as mean ± SD of 4–5 independent experiments.
*p < 0.05 compared to control group-HSA; **p < 0.05 compared
with AGE-Glucose.
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MiR-15a was down-regulated in the plasma of diabetic pa-
tients [27] and in β-cells exposed to high glucose (33 mM
equivalent to 600 mg/dl) for long periods [34]. Mir-15a
was also found to be up-regulated in endothelial cells and
vascular smooth muscle cells after stimulation with KLF4,
which indicate an option to suppress proliferative vascular
disorders [35]. MiR-20b was down-regulated in the plasma
of diabetic patients [27] and similarly expressed in normal
and diabetic dermatological tissue, but was significantly
different from that of diabetic wounds during the course
of healing [36]. To our knowledge, no study has investi-
gated the effect of diabetes and vitamin D on the function
of miR-20b in endothelial cells.
Using pediatric cancer stem cells, Sanchez-Diaz et al.
[37] showed that miR-181c regulate cell proliferation and
the cell cycle, probably by affecting the Notch signaling
pathway and the bone morphogenetic protein (BMP) path-
way. Becker et al. [33] demonstrated that under the influ-
ence of anabolic steroids, miR-181c was down-regulated in
bovine liver and might lead to uncontrolled proliferation in
the liver.
To our knowledge, no study has investigated the effect
of diabetes and vitamin D on the function of miR-181C
in endothelial cells.
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down regulated in a diabetic environment were signifi-
cantly up-regulated after addition of calcitriol. To the
best of our knowledge, this is the first demonstration of
the effect of calcitriol on the expression of these three
miRNA under diabetic-like conditions in HUVEC.
In order to determine the potential genes involved in
HUVEC exposed to a diabetic-like environment and cal-
citriol, we analyzed the predicted target genes of these 3
miRNA (miR-15a, miR-20b and miR-181c).
Seven predicted targets of the 3 deregulated miRNA
were chosen for further analysis of the molecular path-
ways. In Figure 3, we observed that the target genes
KLF9, KLF10, and KLF6 are directly and indirectly (via
TXN, JUN and FOS) bound to TXNIP and to IL8 and
correspond to immune, defense and metabolic biological
processes. After calcitriol was added to the cells, we ob-
served a down-regulation in KLF9, KLF10, KLF6, TXNIP
and IL8 expression. These findings were negatively cor-
related with the miRNA expression patterns and there-
fore support their function.
Kruppel-like factors are members of the zinc finger
family of transcription factors that regulate cellular dif-
ferentiation and tissue development [38,39]. KLF9 is a
transcriptional regulator that is highly expressed in the
rat brain, kidney, lung, and testis and regulates uterine
endometrial cell proliferation, adhesion and differenti-
ation [40,41]. Panda et al. [42] showed that in Ishikawa
cells (an endometrial adenocarcinoma cell line), miR-200c
increased cell proliferation through KLF9 repression.
KLF10 plays a major role in mediating the effects of
TGF-β through regulation of the Smad signaling path-
way. It regulates gene transcription, inhibits cell prolifer-
ation, induces apoptosis and plays a role in activating
the inflammatory response, including stress-induced in-
flammation, leading to increases in cardiovascular dis-
eases, autoimmune abnormalities and DM [43]. Yang
et al. [22] showed that KLF10 induced endothelial cells
to facilitate a possible pathway for TGF-β and regulated
COX-1, which affects platelet aggregation. Using micro-
array gene expression, we demonstrated that in vascular
smooth muscle cells, KLF10 was up-regulated under
diabetic conditions and down-regulated after calcitriol
was added [17]. In this study, calcitriol had also a bene-
ficial effect on KLF10 mRNA expression in HUVEC ex-
posed to a diabetic environment.
KLF6 is one of the KLFs that are reportedly expressed
in endothelial cells and is considered a damage-response
factor [38,39,44]. KLF6 promotes tissue remodeling due
to its ability to activate genes that are members of the
TGF-β signaling pathway, which are implicated in vascu-
lar remodeling, tumor metastasis and apoptosis [39,43].
Qi et al. [45] demonstrated that KLF6 was induced by
high glucose concentrations (30 mmol/l equivalent to600 mg/dl) in human kidney cells and binds to the TXNIP
promoter region. In addition, in an in vivo study in dia-
betic rats, they showed that KLF6 and PPAR-γ (localized
downstream of KLF6) play a key role in the regulation of
TXNIP expression in the development of diabetes melli-
tus. The KLF target genes that were analyzed in this study
and were found to be modified by a diabetic-like environ-
ment and calcitriol might provide unique information on
the function of these transcription factors in endothelial
cells and may be the basis of attractive research in the fu-
ture in the field of DM in animal models and humans.
TXNIP is stimulated by high glucose concentrations.
It is well-demonstrated that it promotes oxidative stress
and apoptosis in several types of cells, including endo-
thelial cells [15,46,47]. In this study, we showed that
TXNIP mRNA expression in cultured HUVEC was up-
regulated following exposure to a diabetic-like environ-
ment, while no significant changes was observed after
the addition of calcitriol. IL8 is produced in several tis-
sues, as well as in endothelial cells upon infection, in-
flammation, ischemia and trauma [48]. We found that
diabetic-like conditions stimulate the expression of this
inflammation-related protein and that the addition of
calcitriol had a beneficial effect on its expression.
Vitamin D deficiency and supplementation
It has been well established that vitamin D deficiency is
correlated with high body fat and glucose levels and de-
creased insulin sensitivity. It is also an independent cardio-
vascular risk factor that predicts poor cardiovascular
outcomes [49-51]. Grineva et al. [49] showed that in
women at late reproductive age (mean age 46.1 ± 4.5) from
the North‐West region of Russia, low 25(OH)D levels
were associated with obesity, increased plasma glucose
levels after OGTT and insulin resistance. A significant
correlation between fasting insulin, 2 h OGTT glucose, in-
sulin levels and low 25(OH)D levels was found in over-
weight and obese subpopulations. The authors suggested
that vitamin D supplementation could be effective in the
prevention of obesity and insulin resistance [49]. The
intervention between obesity, vitamin D and PTH is
complex, suggesting possible effects at different levels.
Alkharfy et al. [50] showed a beneficial effect of vitamin D
supplementation in the metabolic profile of DM type 2 pa-
tients treated with insulin and oral hypoglycemic agents.
The authors suggested that the effect of the medication
could be mediated by an increase in HDL-cholesterol
levels, particularly by vitamin D [50]. Al-Daghri et al. [51]
showed an improvement in LDL, total cholesterol and
in homeostasis model assessment of β-cell function
(HOMA-β) among a Saudi DM type 2 population re-
ceiving vitamin D3 supplementation for 18 months. This
effect was more pronounced in women than in men.
Vitamin D supplementation was suboptimal, which could
Zitman-Gal et al. Cardiovascular Diabetology 2014, 13:8 Page 9 of 10
http://www.cardiab.com/content/13/1/8explain the absence of significant increase in HDL-
cholesterol levels and the increase in HOMA-insulin
resistance index. Moreover the absence of relevant infor-
mation concerning the anti-diabetic drugs and the diet
composition of the patients could have limited the impact
of the results [51].
Ongoing studies should provide an answer to the still-
debated question, whether vitamin D supplementation
can positively influence cardiovascular outcomes. Our
study showed that vitamin D can influence the pro-
atherogenic and inflammatory response seen in DM and
therefore, might contribute to a preventive and therapeutic
effect. Moreover, recent study showed that vitamin D may
improve endothelial function in cardiovascular diseases
and could possibly have a role in vascular protection [52].
Conclusions
In this study, we tried to mimic a diabetic-like environment
in vitro and added vitamin D to simulate the replacement
therapy frequently given to vitamin D deficient patients
with DM. Vitamin D deficiency might have a negative ef-
fect on endothelial cell functions. Treating these patients
to obtain normalization of their vitamin D reserves might
improve the cellular physiology process. New miRNA, as
well as new target genes were found to be differentially
expressed following exposure to physiological concentra-
tions of vitamin D. Further investigation is needed to study
the specific role of these miRNA, including their target
genes and the related molecular and biological pathways.
These findings might in the future contribute to under-
standing the role of vitamin D in treating patients with
DM, including detecting new miRNA markers.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The individual contributions of each co-author are detailed below: TZG and
SB conception and design of research; TZG and JG performed experiments;
TZG and MPC analyzed data, interpreted results of experiments and prepared
figures; TZG and JG drafted manuscript; TZG, SB, EG and JB edited and
revised manuscript; TZG and SB approved final version of manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Faye Ginsberg –Toronto Research Fund in
Diabetes (E. Golan), The Hendrik and Irene Gutwirth MD Thesis Research
Scholarships in Diabetes Mellitus (S. Benchetrit) and the Dr. Yechezkiel and
Pearl Klayman Cathedra of Urology (J. Bernheim) from the Sackler Faculty of
Medicine, Tel Aviv University.
We would to thank Mrs. L. Astrologo from PH&T (SpA, Milan, Italy) who very
kindly provided us with calcitriol.
Author details
1Renal Physiology Laboratory, Department of Nephrology and Hypertension,
Meir Medical Center, Kfar Saba 44281, Israel. 2Bioinformatics Unit, The G. S.
Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. 3Sackler
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Received: 11 October 2013 Accepted: 11 December 2013
Published: 7 January 2014References
1. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350–355.
2. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP:
The widespread impact of mammalian MicroRNAs on mRNA repression
and evolution. Science 2005, 310:1817–1821.
3. Lorenzen J, Kumarswamy R, Dangwal S, Thum T: MicroRN in diabetes and
diabetes-associated complications. RNA Biol 2012, 9:820–827.
4. Magenta A, Greco S, Gaetano C, Martelli F: Oxidative stress and microRNAs
in vascular diseases. Int J Mol Sci 2013, 14:17319–17346.
5. Caporali A, Meloni M, Völlenkle C, Bonci D, Sala-Newby GB, Addis R, Spinetti G,
Losa S, Masson R, Baker AH, Agami R, le Sage C, Condorelli G, Madeddu P,
Martelli F, Emanueli C: Deregulation of microRNA-503 contributes to
diabetes mellitus-induced impairment of endothelial function and reparative
angiogenesis after limb ischemia. Circulation 2011, 123:282–291.
6. Yamagishi S: Cardiovascular disease in recent onset diabetes mellitus.
J Cardiol 2011, 57:257–262.
7. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002,
287:2570–2581.
8. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M:
Hyperglycemia and glycation in diabetic complications. Antioxid Redox
Signal 2009, 11:3071–3109.
9. Madonna R, De Caterina R: Cellular and molecular mechanisms of
vascular injury in diabetes - Part I: pathways of vascular disease in
diabetes. Vascul Pharmacol 2011, 54:68–74.
10. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VWM: Endothelial
dysfunction and diabetes: role of hyperglycaemia, impaired insulin
signalling and obesity. Cell Tissue Res 2009, 335:165–189.
11. Puddu A, Viviani GL: Advanced glycation endproducts and diabetes.
Beyond vascular complications. Endocr Metab Immune Disord Drug Targets
2011, 11:132–140.
12. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation End
products sparking the development of diabetic vascular injury.
Circulation 2006, 114:597–605.
13. Rashid G, Benchetrit S, Fishman D, Bernheim J: Effect of advanced
glycation end products (AGEs) on gene expression and synthesis of
TNF-alpha and endothelial nitric oxide synthase by endothelial cells.
Kidney Int 2004, 66:1099–1110.
14. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, Rashid G:
Calcitriol blunts the deleterious impact of advanced glycation end
products (AGEs) on endothelial cells. Am J Physiol Renal Physiol 2008,
294:1059–1064.
15. Zitman-Gal T, Green J, Pasmanik-Chor M, Oron-Karni V, Bernheim J:
Endothelial pro-atherosclerotic response to extracellular diabetic-like
environment: possible role of thioredoxin-interacting protein.
Nephrol Dial Transplant 2010, 25:2141–2149.
16. Zitman-Gal T, Golan E, Green J, Bernheim J, Benchetrit S: Vitamin D
receptor activation in a diabetic-like environment: potential role on the
endothelial pro-inflammatory and thioredoxin pathways activity.
SBMB 2012, 132:1–7.
17. Zitman-Gal T, Green J, Pasmanik-Chor M, Oron-Karni V, Bernheim J, Benchetrit S:
Vitamin D and vascular smooth muscle cells: gene modulation following
exposure to a diabetic-like environment. J Diabetes Metab 2012, 3:8.
18. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL: Antiproliferative
effects of 1α, 25-dihydroxyvitamin D (3) and vitamin D analogs on
tumor-derived endothelial cells. Endocrinology 2002, 143:2508–2514.
19. Ford ES, Ajani UA, McGuire LC, Liu S: Concentrations of serum vitamin D
and the metabolic syndrome among U.S. adults. Diabetes Care 2005,
28:1228–1230.
20. Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357:266–281.
21. Wu Z, Wang S: Role of kruppel-like transcription factors in adipogenesis.
Dev Biol 2013, 373:235–243.
22. Yang DH, Hsu CF, Lin CY, Guo JY, Yu WC, Chang VH: Krüppel-like factor 10
upregulates the expression of cyclooxygenase 1 and further modulates
angiogenesis in endothelial cell and platelet aggregation in gene-deficient
mice. Int J Biochem Cell Biol 2013, 45:419–428.
23. Kapeller J, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H,
Burwinkel B, Autschbach F, Funke B, Lasitschka F, Gassler N, Fischer C,
Whorwell PJ, Atkinson W, Fell C, Büchner KJ, Schmidtmann M, van der Voort I,
Wisser AS, Berg T, Rappold G, Niesler B: First evidence for an association of a
functional variant in the microRNA-510 target site of the serotonin
Zitman-Gal et al. Cardiovascular Diabetology 2014, 13:8 Page 10 of 10
http://www.cardiab.com/content/13/1/8receptor-type 3E gene with diarrhea predominant irritable bowel
syndrome. Hum Mol Genet 2008, 1(17):2967–2977.
24. Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Raja KR, Hodek J,
Ovesna J, Michalek J: microRNA-342, microRNA-191 and microRNA-510
are differentially expressed in T regulatory cells of type 1 diabetic
patients. Cell Immunol 2010, 260:70–74.
25. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG,
Stainier DY, Srivastava D: miR-126 regulates angiogenic signaling and
vascular integrity. Dev Cell 2008, 15:272–284.
26. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA,
Bassel-Duby R, Olson EN: The endothelial-specific microRNA miR-126
governs vascular integrity and angiogenesis. Dev Cell 2008, 15:261–271.
27. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A,
Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M: Plasma
microRNA profiling reveals loss of endothelial miR-126 and other
microRNAs in type 2 diabetes. Circ Res 2010, 107:810–817.
28. Fichtlscherer S, Zeiher AM, Dimmeler S: Circulating microRNAs: biomarkers
or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol
2011, 31:2383–2390.
29. Waltenberger J, Lange J, Kranz A: Vascular endothelial growth
factor-A-induced chemotaxis of monocytes is attenuated in patients with
diabetes mellitus: a potential predictor for the individual capacity to
develop collaterals. Circulation 2000, 102:185–190.
30. Shu SY, Qing D, Wang B, Zeng QY, Chen YC, Jin Y, Zeng CC, Bao R:
Comparison of microRNA expression in hippocampus and the marginal
division (MrD) of the neostriatum in rats. J Biomed Sci 2013, 20:9.
31. Harafuji N, Schneiderat P, Walter MC: Chen YW: miR-411 is up-regulated in
FSHD myoblasts and suppresses myogenic factors. Orphanet J Rare Dis
2013, 8:55.
32. Druz A, Chen YC, Guha R, Betenbaugh M, Martin SE, Shiloach J: Large-scale
screening identifies a novel microRNA, miR-15a-3p, which induces
apoptosis in human cancer cell lines. RNA Biol 2013, 10:287–300.
33. Becker C, Riedmaier I, Reiter M, Tichopad A, Pfaffl MW, Meyer HH: Changes
in the miRNA profile under the influence of anabolic steroids in bovine
liver. Analyst 2011, 136:1204–1209.
34. Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM: MicroRNA-15a positively
regulates insulin synthesis by inhibiting uncoupling protein-2 expression.
Diabetes Res Clin Pract 2011, 91:94–100.
35. Zheng X, Li A, Zhao L, Zhou T, Shen Q, Cui Q, Qin X: Key role of microRNA-15a
in the KLF4 suppressions of proliferation and angiogenesis in endothelial
and vascular smooth muscle cells. Biochem Biophys Res Commun. 2013,
437:625–3.
36. Madhyastha R, Madhyastha H, Nakajima Y, Omura S, Maruyama M:
MicroRNA signature in diabetic wound healing: promotive role of
miR-21 in fibroblast migration. Int Wound J 2012, 9:355–361.
37. Sanchez-Diaz PC, Hsiao TH, Chang JC, Yue D, Tan MC, Chen HI, Tomlinson GE,
Huang Y, Chen Y, Hung JY: De-regulated MicroRNAs in pediatric cancer
stem cells target pathways involved in cell proliferation. Cell Cycle and
Development. PLoS One 2013, 8:e61622.
38. Bieker JJ: Kruppel-like factors: three fingers in many pies. J Biol Chem
2001, 276:34355–34358.
39. Atkins GB, Jain MK: Role of Kruppel-like transcription factors in endothelial
biology. Circ Res 2007, 100:1686–1695.
40. Simmen RC, Pabona JM, Velarde MC, Simmons C, Rahal O, Simmen FA: The
emerging role of Krüppel-like factors in endocrine-responsive cancers of
female reproductive tissues. J Endocrinol 2010, 204:223–231.
41. Simmen FA, Su Y, Xiao R, Zeng Z, Simmen RCM: The Krüppel-like factor 9
(KLF9) network in HEC-1-A endometrial carcinoma cells suggests the
carcinogenic potential of dys-regulated KLF9 expression. Reprod Biol
Endocrinol 2008, 6:41.
42. Panda H, Pelakh L, Chuang TD, Luo X, Bukulmez O, Chegini N: Endometrial
miR-200c is altered during transformation into cancerous states and
targets the expression of ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5.
Reprod Sci 2012, 19:786–796.
43. Subramaniam M, Hawse JR, Rajamannan NM, Ingle JN, Spelsberg TC:
Functional role of KLF10 in multiple disease processes. Biofactors 2010,
36:8–18.
44. Garrido-Martín EM, Blanco FJ, Roquè M, Novensà L, Tarocchi M, Lang UE,
Suzuki T, Friedman SL, Botella LM, Bernabéu C: Vascular injury triggers
Krüppel-like factor 6 mobilization and cooperation with specificityprotein 1 to promote endothelial activation through upregulation of the
activin receptor-like kinase 1 gene. Circ Res 2013, 112:113–127.
45. Qi W, Chen X, Holian J, Tan CY, Kelly DJ, Pollock CA: Transcription factors
Krüppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma}
mediate high glucose-induced thioredoxin-interacting protein. Am J Pathol
2009, 175:1858–1867.
46. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT: Hyperglycemia
promotes oxidative stress through inhibition of thioredoxin function by
thioredoxin-interacting protein. J Biol Chem 2004, 279:30369–30374.
47. Yamawaki H: Thioredoxin: a multifunctional antioxidant enzyme in
kidney, heart and vessels. Curr Opin Nephrol Hypertens 2005, 14:149–153.
48. Baggiolini M, Clark-Lewis I: Interleukin-8, a chemotactic and inflammatory
cytokine. FEBS Lett 1992, 307:97–101.
49. Grineva EN, Karonova T, Micheeva E, Belyaeva O, Nikitina IL: Vitamin D
deficiency is a risk factor for obesity and diabetes type 2 in women at
late reproductive age. Aging (Albany NY). 2013, 5:575–81.
50. Alkharfy KM, Al-Daghri NM, Sabico SB, Al-Othman A, Moharram O, Alokail MS,
Al-Saleh Y, Kumar S, Chrousos GP: Vitamin D supplementation in patients
with diabetes mellitus type 2 on different therapeutic regimens: a one-year
prospective study. Cardiovasc Diabetol 2013, 12:113.
51. Al-Daghri NM, Alkharfy KM, Al-Othman A, El-Kholie E, Moharram O, Alokail MS,
Al-Saleh Y, Sabico S, Kumar S, Chrousos GP: Vitamin D supplementation as an
adjuvant therapy for patients with T2DM: an 18-month prospective
interventional study. Cardiovasc Diabetol 2012, 11:85.
52. Kienreich K, Tomaschitz A, Verheyen N, Pieber T, Gaksch M, Grübler MR,
Pilz S: Vitamin D and cardiovascular disease. Nutrients 2013, 5:3005–3021.
doi:10.1186/1475-2840-13-8
Cite this article as: Zitman-Gal et al.: Vitamin D manipulates miR-181c,
miR-20b and miR-15a in human umbilical vein endothelial cells exposed
to a diabetic-like environment. Cardiovascular Diabetology 2014 13:8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
